Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. CSPHF.PINK

CStone Pharmaceuticals (CSPHF PINK) stock market data APIs

$0.114 0(0%) as of July 25, 2024
Price chart is built with Anychart

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.

CStone Pharmaceuticals Financial Data Overview

0.114
0.114
-
0.114
0.114
0.114-0.362
548 M
1 275 M
464 M
-0.0519
0.183
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CSPHF',
Type: 'Common Stock',
Name: 'CStone Pharmaceuticals',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00RP1HQC1',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

CStone Pharmaceuticals Fundamental Data is available in our Financial Data APIs

  • Net Revenue 464 M
  • EBITDA -586 641 024
  • Earnings Per Share -0.04
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get CStone Pharmaceuticals Earnings via APIs

  • Latest Release 2021-06-30
  • EPS/Forecast 0

Get CStone Pharmaceuticals End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get CStone Pharmaceuticals latest news via APIs

CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore

The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. The deal enables Servier to potentially bring additio...

CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metast...
Do you have any questions?
support@eodhistoricaldata.com